Literature DB >> 11910185

Viper venom components affecting angiogenesis.

T F Huang1, C H Yeh, W B Wu.   

Abstract

Angiogenesis is a complex process consisting of the proliferation, migration and differentiation of endothelial cells, and it is essential for the progression of malignant solid tumors. In this report, we examine the effects of disintegrins (e.g. rhodostomin and accutin) and glycoprotein-lb-binding proteins (e.g. agkistin) on each step in angiogenesis using in vitro and in vivo models. Rhodostomin (but not agkistin) inhibited the viability of human umbilical vein endothelial cells (HUVECs) and capillary tube formation of HUVECs. Rhodostomin also inhibited HUVEC migration and invasion evoked by basic fibroblast growth factor (bFGF). In in vivo studies, rhodostomin inhibited bFGF-, but not vascular-endothelial-growth-factor (VEGF)- associated angiogenesis in chick chorioallantoic membrane model, blocked both bFGF and B16F10 melanoma cell-induced neovascularization, and suppressed the growth of subcutaneously inoculated B16F10 solid tumor, leading to a prolonged survival of the C57BL/6 mice treated with rhodostomin. The antiangiogenic effects of rhodostomin on bFGF-treated HUVECs may be mainly related to the blockade of the interaction of endothelial alpha(v)beta(3) and extracellular matrix. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11910185     DOI: 10.1159/000048063

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  9 in total

1.  Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential.

Authors:  Radu Minea; Corey Helchowski; Barbara Rubino; Kyle Brodmann; Stephen Swenson; Francis Markland
Journal:  Toxicon       Date:  2011-02-24       Impact factor: 3.033

2.  Anti-metastatic activity of the recombinant disintegrin, r-mojastin 1, from the Mohave rattlesnake.

Authors:  Sara Lucena; Elda E Sanchez; John C Perez
Journal:  Toxicon       Date:  2011-02-18       Impact factor: 3.033

3.  Inhibition of melanoma cell motility by the snake venom disintegrin eristostatin.

Authors:  Jing Tian; Carrie Paquette-Straub; E Helene Sage; Sarah E Funk; Vivek Patel; Deni Galileo; Mary Ann McLane
Journal:  Toxicon       Date:  2007-01-10       Impact factor: 3.033

4.  Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities.

Authors:  Radu O Minea; Corey M Helchowski; Samuel J Zidovetzki; Fritz K Costa; Stephen D Swenson; Francis S Markland
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

Review 5.  Applications of snake venom components to modulate integrin activities in cell-matrix interactions.

Authors:  Cezary Marcinkiewicz
Journal:  Int J Biochem Cell Biol       Date:  2013-06-26       Impact factor: 5.085

6.  Anti-angiogenic activities of two recombinant disintegrins derived from the Mohave and Prairie rattlesnakes.

Authors:  Sara E Lucena; Karen Romo; Montamas Suntravat; Elda E Sánchez
Journal:  Toxicon       Date:  2013-11-20       Impact factor: 3.033

Review 7.  Antitumoral activity of snake venom proteins: new trends in cancer therapy.

Authors:  Leonardo A Calderon; Juliana C Sobrinho; Kayena D Zaqueo; Andrea A de Moura; Amy N Grabner; Maurício V Mazzi; Silvana Marcussi; Auro Nomizo; Carla F C Fernandes; Juliana P Zuliani; Bruna M A Carvalho; Saulo L da Silva; Rodrigo G Stábeli; Andreimar M Soares
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

8.  Anti-angiogenic potential of an ethanol extract of Annona atemoya seeds in vitro and in vivo.

Authors:  Jin-Mu Yi; Jong-Shik Park; Jun Lee; Jin Tae Hong; Ok-Sun Bang; No Soo Kim
Journal:  BMC Complement Altern Med       Date:  2014-09-23       Impact factor: 3.659

Review 9.  Processing of Snake Venom Metalloproteinases: Generation of Toxin Diversity and Enzyme Inactivation.

Authors:  Ana M Moura-da-Silva; Michelle T Almeida; José A Portes-Junior; Carolina A Nicolau; Francisco Gomes-Neto; Richard H Valente
Journal:  Toxins (Basel)       Date:  2016-06-09       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.